Sign In
Buy MRK
$115.49
+0.320 (+0.278%)
At Close: Jun 17, 2026
Why Moderna Stock Is Sliding Today
04:05pm, Tuesday, 16'th Aug 2022 The Motley Fool
There wasn't any negative news from the vaccine maker.
Seagen For Sale? This Acquisition Target Is 'Too Intriguing To Ignore,' RBC Says
03:03pm, Tuesday, 16'th Aug 2022 Benzinga
The recent pressure on Seagen Inc.’s (NASDAQ: SGEN) stock may offer a nearer-term opportunity, but the biotech's position as an attractive strategic target is “too intriguing to ignore.”
That's
3 Top Stocks to Invest In Right Now
01:58pm, Tuesday, 16'th Aug 2022
Do you think I'd be writing for InvestorPlace if I knew the three top stocks to invest in right now? Of course not.
Here's what investors should do as the housing market faces tough times
01:40pm, Tuesday, 16'th Aug 2022 MarketWatch
The housing market is swirling with trouble, but probably not a bubble says our call of the day.
AstraZeneca's (AZN) Lynparza sNDA Gets FDA Priority Tag
12:50pm, Tuesday, 16'th Aug 2022 Zacks Investment Research
FDA grants priority review to AstraZeneca (AZN) and Merck's (MRK) Lynparza as a combination therapy for patients with metastatic castration-resistant prostate cancer.
Is Invesco Dow Jones Industrial Average Dividend ETF (DJD) a Strong ETF Right Now?
10:20am, Tuesday, 16'th Aug 2022 Zacks Investment Research
Smart Beta ETF report for DJD
Merck and Orna Therapeutics to collaborate in deal entitling Orna to up to $3.5 billion in milestone payments
07:01am, Tuesday, 16'th Aug 2022
Merck MRK, -0.46% and privately held Orna Therapeutics said Tuesday they have agreed to collaborate to discover and develop programs, including vaccines and therapeutics, in the fields of infectious d
Illumina (ILMN) Q2 Earnings Miss Estimates, Slashes '22 View
01:34pm, Monday, 15'th Aug 2022 Zacks Investment Research
Robust sales contribution across operating segments drove Illumina's (ILMN) Q2 top line.
Investors Heavily Search Merck & Co., Inc. (MRK): Here is What You Need to Know
01:00pm, Monday, 15'th Aug 2022 Zacks Investment Research
Zacks.com users have recently been watching Merck (MRK) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
bluebird bio (BLUE) Focused on Pipeline Amid Marketed Drug Dearth
12:51pm, Monday, 15'th Aug 2022 Zacks Investment Research
bluebird bio's (BLUE) efforts to develop its gene-therapy pipeline are impressive. The FDA is reviewing BLUE's filing for beti-cel as a treatment for beta thalassemia and eli-cel for cerebral adrenole
National Vision (EYE) Q2 Earnings Top Mark, Revenue View Cut
11:11am, Monday, 15'th Aug 2022 Zacks Investment Research
National Vision (EYE) is simultaneously facing demand headwinds across its network of stores, given the current macro environment, as well as supply challenges.
Wall Street Breakfast: China The Outlier
10:57am, Monday, 15'th Aug 2022 Seeking Alpha
Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha, iTunes, Stitcher and Spotify.
Should You Invest in the VanEck Pharmaceutical ETF (PPH)?
10:20am, Monday, 15'th Aug 2022 Zacks Investment Research
Sector ETF report for PPH
10 defensive stocks that can also provide you with growth and dividends over the long term
01:34pm, Saturday, 13'th Aug 2022 MarketWatch
Professional money managers have a strong preference for one stock sector in particular, along with cash dividends.
ResMed (RMD) Q4 Earnings Beat Estimates, Gross Margin Up
07:34pm, Friday, 12'th Aug 2022 Zacks Investment Research
ResMed (RMD) posts better-than-expected Q4 results with continued strength in sleep and respiratory care devices sales performance.
